Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis

References

• Cooper I, Mondal A, Antonopoulos CG. A SIR model assumption for the spread of COVID-19 in different communities. Chaos Solit Fractals. 2020 Oct;139:110057.
   PubMed Web of Science ®Google Scholar
• Kutsuna S. Clinical manifestations of coronavirus disease 2019. JMA J. 2021 Apr 15;4(2):76–80.
   PubMedGoogle Scholar
• Kox M, Waalders NJB, Kooistra EJ, et al. Cytokine levels in critically Ill patients with COVID-19 and other conditions. JAMA. 2020 Sep 3;324(15):1565–1567.
   PubMed Web of Science ®Google Scholar
• Zhu J, Pang J, Ji P, et al. Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis. J Med Virol. 2021 Jan;93(1):35–37.
   PubMed Web of Science ®Google Scholar
• Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020 May;27(5):1451–1454.
   PubMed Web of Science ®Google Scholar
• Udomsinprasert W, Jittikoon J, Sangroongruangsri S, et al. Circulating levels of interleukin-6 and interleukin-10, but not tumor necrosis factor-alpha, as potential biomarkers of severity and mortality for COVID-19: systematic review with meta-analysis. J Clin Immunol. 2021 Jan;41(1):11–22.
   PubMed Web of Science ®Google Scholar
• Liu C, Zhou Q, Li Y, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci. 2020 Mar 25;6(3):315–331.
   PubMed Web of Science ®Google Scholar
• Zhong J, Tang J, Ye C, et al. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol. 2020 Jul;2(7):e428–e436.
   PubMedGoogle Scholar
• Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020 Apr 27:ciaa478. [Epub ahead of print.]
   Google Scholar
• COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health, 2020.
   Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–e34.
   PubMed Web of Science ®Google Scholar
• Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019 Oct 3;10:Ed000142.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Thorlund K, Oxman AD, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol. 2013 Feb;66(2):173–183.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 – final report. N Engl J Med. 2020 Nov 5;383(19):1813–1826.
   PubMed Web of Science ®Google Scholar
• Declercq J, Van Damme KFA, De Leeuw E, et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respir Med. 2021 Dec;9(12):1427–1438.
   PubMed Web of Science ®Google Scholar
• Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021 Apr 22;384(16):1491–1502.
   PubMed Web of Science ®Google Scholar
• Hermine O, Mariette X, Tharaux PL, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021 Jan 1;181(1):32–40.
   PubMed Web of Science ®Google Scholar
• Hermine O, Mariette X, Porcher R, et al. Effect of Interleukin-6 Receptor Antagonists in Critically Ill Adult Patients with COVID-19 Pneumonia: two Randomised Controlled Trials of the CORIMUNO-19 Collaborative Group. Eur Respir J. 2022 Feb 3:2102523. [Epub ahead of print.]
   Web of Science ®Google Scholar
• Recovery Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 May 1;397(10285):1637–1645.
   PubMed Web of Science ®Google Scholar
• Corimuno-Collaborative Group. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): an open-label randomised controlled trial. Lancet Rheumatol. 2022 Jan;4(1):e24–e32.
   PubMedGoogle Scholar
• Lescure FX, Honda H, Fowler RA, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 May;9(5):522–532.
   PubMed Web of Science ®Google Scholar
• Merchante N, Cárcel S, Garrido-Gracia JC, et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0210721.
   PubMed Web of Science ®Google Scholar
• Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021 Apr 22;384(16):1503–1516.
   PubMed Web of Science ®Google Scholar
• Rosas IO, Diaz G, Gottlieb RL, et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med. 2021 Nov;47(11):1258–1270.
   PubMed Web of Science ®Google Scholar
• Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021 Jan 7;384(1):20–30.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021 Jan 1;181(1):24–31.
   PubMed Web of Science ®Google Scholar
• Sancho-López A, Caballero-Bermejo AF, Ruiz-Antorán B, et al. Efficacy and safety of sarilumab in patients with COVID19 pneumonia: a randomized, phase III clinical trial (SARTRE study). Infect Dis Ther. 2021 Dec;10(4):2735–2748.
   PubMed Web of Science ®Google Scholar
• Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021 May;9(5):511–521.
   PubMed Web of Science ®Google Scholar
• Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020 Dec 10;383(24):2333–2344.
   PubMed Web of Science ®Google Scholar
• Veiga VC, Prats J, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021 Jan 20;372:n84.
   PubMed Web of Science ®Google Scholar
• Avni T, Leibovici L, Cohen I, et al. Tocilizumab in the treatment of COVID-19-a meta-analysis. QJM. 2021 Nov 5;114(8):577–586.
   PubMed Web of Science ®Google Scholar
• Aziz M, Haghbin H, Abu Sitta E, et al. Efficacy of tocilizumab in COVID-19: a systematic review and meta-analysis. J Med Virol. 2021;93(3):1620–1630.
   PubMed Web of Science ®Google Scholar
• Belletti A, Campochiaro C, Marmiere M, et al. Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials. Ann Intensive Care. 2021 Oct 26;11(1):152.
   PubMed Web of Science ®Google Scholar
• Malgie J, Schoones JW, Pijls BG. Decreased mortality in coronavirus disease 2019 patients treated with tocilizumab: a rapid systematic review and meta-analysis of observational studies. Clin Infect Dis. 2021 Jun 1;72(11):e742–e749.
   PubMed Web of Science ®Google Scholar
• Shankar-Hari M, Vale CL, Godolphin PJ, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021 Aug 10;326(6):499–518.
   PubMed Web of Science ®Google Scholar
• Cortegiani A, Ippolito M, Greco M, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology. 2021 Jan–Feb;27(1):52–66.
   PubMed Web of Science ®Google Scholar
• Tleyjeh IM, Kashour Z, Riaz M, et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update. Clin Microbiol Infect. 2021 Aug;27(8):1076–1082.
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693–704.
   PubMed Web of Science ®Google Scholar
• Li N, Jie Z. The application of corticosteroids in COVID-19: a two-edged sword. J Transl Int Med. 2020 Jun;8(2):66–70.
   PubMed Web of Science ®Google Scholar
• Petrak RM, Van Hise NW, Skorodin NC, et al. Early tocilizumab dosing is associated with improved survival in critically Ill patients infected with severe acute respiratory syndrome coronavirus-2. Crit Care Explor. 2021 Apr;3(4):e0395.
   PubMedGoogle Scholar